

**For investors**

+1 858.836.5000

investorrelations@resmed.com

For media

+1 619.510.1281

news@resmed.com

ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025

SAN DIEGO, January 9, 2025 – ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

- Location: <https://investor.resmed.com>
- Date: Thursday, January 30, 2025
- Time: 1:30 p.m. PST / 4:30 p.m. EST
- International: London, Thursday, January 30, 2025, 9:30 p.m. GMT
Sydney, Friday, January 31, 2025, 8:30 a.m. AEDT

Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.

A replay of the earnings webcast will be accessible on ResMed's website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from January 30, 2025, until February 13, 2025, at:

- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13750689

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

###